Biognosys (RUO, biopharma)

Protein mapping and analysis aimed at modeling cancer cell pathways and identifying biomarkers.

Vetted listing

Testing

Consented intake · your records travel with you · nothing moves without your sign-off

Why Biognosys exists

Biognosys provides proteomics services, mapping and analyzing proteins by mass spectrometry or target capture from blood or FFPE tissue. The goal is to model the signature pathways of cancer cells to identify biomarkers and inform treatment thinking. Its work is research use only and oriented toward biopharma rather than direct clinical patient testing.

Named partners · Bruker, Alamar Biosciences, IonOpticksCollaboration network · More than 25 collaborators across the life science industry and academia

Prefer the source? Biognosys (RUO, biopharma)'s own site has more.

Share your records

We'll pre-fill the intake from your records — no retyping.

Start sharing →

Check your coverage

See if your insurance covers this and estimate out-of-pocket cost.

Check coverage →

Coverage, insurance & cost

The fastest way to know what you'll pay: check your coverage with your plan. Below is what we know about how Biognosys (RUO, biopharma) handles billing.

We don't have confirmed insurance details for Biognosys (RUO, biopharma) yet. Start a coverage check with your plan, or contact the provider directly.

Ask about this service

Answers grounded in Biognosys's details here. Educational only; your oncologist directs treatment.

Also consider

Other providers in similar categories.

BostonGene

6 offerings

Gather distinctive biomarkers that can guide treatment and monitor disease progression

Foundation Medicine

6 offerings

FoundationOne CDx is an FDA-approved comprehensive genomic profiling test that analyzes 324 genes to identify clinically relevant genomic alterations.